

Consensus to define clinical criteria to assess the efficacy of preventive treatment of episodic and chronic migraine in routine clinical practice.

The objective of this project is to reach a consensus on a tool to assess the efficacy of a prophylactic treatment for chronic or episodic migraine in order to help you and support your decisions in your daily clinical practice.

The questionnaire has 3 blocks:

- 1. Background
- 2. Episodic and chronic migraine assessment and prophylactic treatment
- 3. Patient profiles evaluation

There is no correct or incorrect answer, what we would like to know is your current clinical practice and your opinion on the topics approached in the questionnaire.

Please, answer all questions the more precisely and sincerely you can.

For any doubt or question that may arise while answering the questionnaire do not hesitate to contact us through the following e-mail: <a href="mailto:info@myliferesponse.com">info@myliferesponse.com</a>

Many thanks for your collaboration.

## My-LIFE Response Criteria project team

Please, click here to start the questionnaire

| L. | Background   |                         |  |  |  |  |  |  |
|----|--|-------------------------|--|--|--|--|--|--|
| 1. | Medical specialty:   |                         |  |  |  |  |  |  |
|    | ☐ General practitioner   |                         |  |  |  |  |  |  |
|    |  |                         |  |  |  |  |  |  |
|    | □ Neurologist  |                         |  |  |  |  |  |  |
|    | ☐ Internal Medicine  |                         |  |  |  |  |  |  |
|    | ☐ Psychiatrist   |                         |  |  |  |  |  |  |
|    | Other, please specify:   |                         |  |  |  |  |  |  |
|    | (* if "psychiatrist" or "other", the participation of the panelist will  | be cancelled)           |  |  |  |  |  |  |
| 2. | How many patients do you visit in 1 week?  |                         |  |  |  |  |  |  |
| ۷. | (* if "<29", the participation of the panelist will be cancelled)  |                         |  |  |  |  |  |  |
|    |  |                         |  |  |  |  |  |  |
| 3. | Among those patients, please classify them according to the type suffering from:   | of pathologies they are |  |  |  |  |  |  |
|    | surrening from:  |                         |  |  |  |  |  |  |
|    | Parkinson  | %                       |  |  |  |  |  |  |
|    | Ictus  | %                       |  |  |  |  |  |  |
|    | Migraine   | %                       |  |  |  |  |  |  |
|    | Dementia/Alzheimer   | %                       |  |  |  |  |  |  |
|    | Other  | %                       |  |  |  |  |  |  |
|    | TOTAL  | %                       |  |  |  |  |  |  |
|    |  | * total must sum 100%   |  |  |  |  |  |  |
| 4. | (* if "total number of patients" * "% Migraine patients" is "<2", the panelist will be cancelled)  For how long have you been treating patients with migraine? | e participation of the  |  |  |  |  |  |  |
|    | $\square$ <2 years $\square$ 2-5 years $\square$ 5-10 years $\square$ 10-15 years $\square$ 15-20 year   | rs □ >20 years          |  |  |  |  |  |  |
|    | (* if "< 2years" the participation of the panelist will be cancelled)  |                         |  |  |  |  |  |  |
| 5. | Among those patients suffering from migraine. Please classify the of migraine they are suffering from.   | m according to the type |  |  |  |  |  |  |
|    | Migraine without aura  | %                       |  |  |  |  |  |  |
|    | Migraine with aura   | %                       |  |  |  |  |  |  |
|    | Chronic migraine   | %                       |  |  |  |  |  |  |
|    | Probable migraine  | %                       |  |  |  |  |  |  |
|    | Episodic symptoms that may be associated with migraine   | %                       |  |  |  |  |  |  |
|    | TOTAL  | 100 %                   |  |  |  |  |  |  |

(\* if "Chronic migraine = 0", the participation of the panelist will be cancelled)

<sup>\*</sup> total can sum > 100%

| 0. | Yes □ No  (* if "no", the participation of the panelist will be cancelled)   |
|----|--|
| 7. | Do you currently prescribe prophylactic treatments for episodic or chronic migraine?  Yes, when needed  No, I refer to the specialist (* if "no", the participation of the panelist will be cancelled)   |
| 8. | Among your patients suffering from migraine, how many of them are currently under a prophylactic treatment for chronic migraine? $\bigcirc 0\% \bigcirc <25\% \bigcirc 25-50\% \bigcirc 50-75\% \bigcirc >75\%$ (* if "0%", the participation of the panelist will be cancelled) |

## 2. Chronic migraine assessment and prophylactic treatments

9. When facing a patient with migraine, when do you use de following tools.

|  | Clinical interview | Patient diary | Validated scale<br>to assess chronic<br>migraine | Nothing |
|--|--------------------|---------------|--|---------|
| Diagnostic<br>(1 <sup>st</sup> visit)    | 0                  | 0             | 0  | 0       |
| Follow up visits                         | 0                  | 0             | 0  | 0       |
| Before starting a prophylactic treatment | 0                  | 0             | 0  | 0       |
| During a prophylactic treatment          | 0                  | 0             | 0  | 0       |

<sup>\*</sup> More than one answer is possible

- 10. Among the below mentioned validated scales to assess response to migraine treatment, please indicate if you use it (yes/no).
  - 10.1 When no, please state the main reason why
  - 10.2 When yes, please state the main reason why

| Test  | Reference  | 10.Yes / N | No <u>1</u> ( | 0.1 If No, Why?  | _10.: | 2 If yes. Why?   |
|---|--|------------|---------------|--|-------|--|
| MIDAS<br>(Migraine<br>Disability<br>Assessment)                         | Stewart WF et al.<br>Neurology. 2001;56(6<br>Suppl 1): S20-8.  |            | es o          | I don't know it I know it, but it's not available where I work Outdated Too long/complicated to use in clinical practice It doesn't assess what I need to know | 0 0   | Available where I work Easy to use It assesses what I need It is widely used in publications |
| Migraine<br>Therapy<br>Assessment<br>Questionnaire<br>(MTAQ®)           | Chatterton ML et al.<br>Headache.<br>2002;42(10):1006-15.  |            |               |  |       |  |
| Patient Perception of Migraine Questionnaire (PPMQ) and Revised version | Davis KH et al, Value<br>Health, 2002; 5 (5):422-<br>430<br>Kimel M et al, Cephalalgia,<br>2008; 28:510-523            |            |               |  |       |  |
| Headache<br>Impact Test™-6<br>(HIT-6)                                   | Kosinski M et al. Qual Life<br>Res. 2003;12(8):963-74.   |            |               |  |       |  |
| Brief Headache<br>Screen –<br>Treatment                                 | Maizels M, Burchette R.<br>Headache. 2003;43(5):441-<br>50.  |            |               |  |       |  |
| Migraine Treatment Satisfaction Measure (MTSM)                          | Patrick DL et al, Clinical<br>Therapeutics, 2003, 25:11,<br>2920-2935  |            |               |  |       |  |
| Migraine-ACT<br>(Assessment of<br>Current<br>Therapy)                   | Dowson AJ et al. Curr Med<br>Res Opin. 2004;<br>20(7):1125-35; Kilminster<br>SG et al. Headache.<br>2006;46(4):553-62. |            |               |  |       |  |

| Migraine<br>Prevention<br>Questionnaire<br>(MPQ)                  | Lipton R et al. The Journal<br>of Head and Face Pain<br>(2008) 48                      |
|---|--|
| Migraine<br>Treatment<br>Optimization<br>Questionnaire<br>(M-TOQ) | Lipton RB et al,<br>Cephalalgia (2009), 29,<br>751-759                                 |
| The Completeness of Response Survey (CORS).                       | Coon CD et al, Headache (2012); 52:550-572   |
| Migraine Specific Quality of life questionnaire                   | Caproni et al. BMC<br>Neurology ( <b>2015</b> ) 15:85                                  |
| HURT  | Steiner, T. J., et al. The<br>Journal of Headache and<br>Pain 19.1 <b>(2018</b> ): 15. |

## 11. Considering the following listed criteria, which of them do you use to assess the effectiveness of a prophylactic treatment?

| Criteria                  | Never | Rarely | Sometimes | Usually | Always |
|---------------------------|-------|--------|-----------|---------|--------|
| Treatment tolerability*   | 0     | 0      | 0         | 0       | 0      |
| Frequency of attacks      | 0     | 0      | 0         | 0       | 0      |
| Disability / Intensity of | 0     | 0      | 0         | 0       | 0      |
| the attacks               |       |        |           |         |        |
| Use of acute medication   | 0     | 0      | 0         | 0       | 0      |
| when having an attack     |       |        |           |         |        |
| Duration of the attacks   | 0     | 0      | 0         | 0       | 0      |
| Response to acute         | 0     | 0      | 0         | 0       | 0      |
| medication                |       |        |           |         |        |
| Patient perception of     | 0     | 0      | 0         | 0       | 0      |
| the prophylactic          |       |        |           |         |        |
| treatment                 |       |        |           |         |        |

<sup>\*</sup>Treatment tolerability refers, to the occurrence of side effects

## 3. Patient profiles evaluation

In the next tab you will find different patient profiles defined according to some criteria used to evaluate the effectiveness of a prophylactic treatment for episodic or chronic migraine.

Considering that the patient does not report any side effects related with the prophylactic treatment, you will be requested, for each of the patient profiles, to define if the patient is: Responder, partial responder, non-responder or if you would need more data to take a decision regarding the prophylactic treatment under evaluation. In the case that you decide that more data is needed, please specify, which kind of data you would need. Then, in the last column, please specify if, considering the specified patient profile you would continue with the prophylactic treatment or not.

Then, you will be requested to consider for the same patient profile, the situation of the presence of tolerable side effects, if he responds to prophylactic treatment, and if you would continue with prophylactic treatment.

| Frequency<br>(days with | Disabilty<br>(intensity | Use of acute        | Patient<br>perceptio                      | Patient<br>profile                      | Response to prophylactic | Would you continue with the preventive                    |                                    | f tolerable side  |          |  |
|-------------------------|-------------------------|---------------------|---|---|--------------------------|---|------------------------------------|---|----------|--|
| migraine)               | of the attacks)         | medication          | n of the<br>prophylac<br>tic<br>treatment | rarely found<br>in clinical<br>practice |                          | treatment?  | Response to prophylactic treatment | Would you<br>continue with<br>the<br>prophylactic<br>treatment?       |          |  |
| > 50%<br>reduction      | >50%<br>reduction       | >50%<br>reduction   | >50%<br>reduction                         | Positive  Negative                      | (*)                      | (Pull- down with the ≠ options mentioned in the question) | Yes / No                           | (Pull- down<br>with the ≠<br>options<br>mentioned in<br>the question) | Yes / No |  |
|                         |                         | 25-50%<br>reduction | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         |                         | <25% reduction      | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         | 25-50%<br>reduction     | >50%<br>reduction   | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         |                         | 25-50%<br>reduction | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         |                         | <25%<br>reduction   | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         | <25%<br>reduction       | >50%<br>reduction   | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         |                         | 25-50%<br>reduction | Positive<br>Negative                      |   |                          |   |                                    |   |          |  |
|                         |                         |                     |   | <25%<br>reduction                       | Positive<br>Negative     |   |                                    |   |          |  |

| 49-25% reduction | >50% reduction   | >50% reduction   | Positive |
|------------------|------------------|------------------|----------|
|                  |                  |                  | Negative |
|                  |                  | 25-50% reduction | Positive |
|                  |                  |                  | Negative |
|                  |                  | <25% reduction   | Positive |
|                  |                  |                  | Negative |
|                  | 25-50% reduction | >50% reduction   | Positive |
|                  |                  |                  | Negative |
|                  |                  | 25-50% reduction | Positive |
|                  |                  |                  | Negative |
|                  |                  | <25% reduction   | Positive |
|                  |                  |                  | Negative |
|                  | <25% reduction   | >50% reduction   | Positive |
|                  |                  |                  | Negative |
|                  |                  | 25-50% reduction | Positive |
|                  |                  |                  | Negative |
|                  |                  | <25% reduction   | Positive |
|                  |                  |                  | Negative |
| <25% reduction   | >50% reduction   | >50% reduction   | Positive |
|                  |                  |                  | Negative |
|                  |                  | 25-50% reduction | Positive |
|                  |                  |                  | Negative |
|                  |                  | <25% reduction   | Positive |
|                  |                  |                  | Negative |
|                  | 25-50% reduction | >50% reduction   | Positive |
|                  |                  |                  | Negative |
|                  |                  | 25-50% reduction | Positive |
|                  |                  |                  | Negative |
|                  |                  | <25% reduction   | Positive |
|                  |                  |                  | Negative |
|                  | <25% reduction   | >50% reduction   | Positive |
|                  |                  |                  | Negative |
|                  |                  | 25-50% reduction | Positive |
|                  |                  |                  | Negative |
|                  |                  | <25% reduction   | Positive |
|                  |                  |                  | Negative |

<sup>(\*)</sup> when this cell will be marked the panelist will not be asked to answer the following questions on the specific patient profile.

(\*\*) Tolerable side effects is when the benefit from the prophylactic treatment outweighs the inconveniences from the side effects.

You've reached the end of the questionnaire. Once all answers analyzed you will receive a link to answer the second wave.

Many thanks for your valuable collaboration.

My-LIFE Response Criteria project team